Market Cap$27.03B
P/E56.96x
PEG Ratio2.99
Div yield0.33%
Beta1.15
WST Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)33.42%
Price vs S&P 500 (4W)7.47%
PEG Ratio2.99
VGM Score52.40
P/E Ratio (Annual)56.96x
Indicated Dividend Yield (Annual)0.33%
WST Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.08 | $2.37 | +13.86%(+$0.29) | |
| Q1 2026 | $1.68 | $2.13 | +27.07%(+$0.45) | |
| Q4 2025 | $1.83 | $2.04 | +11.54%(+$0.21) | |
| Q3 2025 | $1.71 | $1.96 | +14.55%(+$0.25) | |
| Q2 2025 | $1.54 | $1.84 | +19.71%(+$0.30) |
WST Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.27
4.22
4.22
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services supplies critical packaging and delivery systems to the pharmaceutical, biotechnology, and generic drug industries. Its products include elastomer-based packaging components, nonglass containment solutions, and auto-injectors for biologics, GLP-1 agonists, and small-molecule drugs. The company derives approximately 80% of revenue from proprietary products and 20% from contract manufacturing, with 55% of revenue from international markets.